Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis

Figure 3

Adhesion of prostate cancer cells to HUVEC. PC-3, DU-145 or LNCaP cells were treated with 1 μM AEE788, 1 mM VPA or 1 nM RAD001, applied alone or in combination. Tumor cells were then added at a density of 0.5 × 106 cells/well to HUVEC monolayers for 1, 2 or 4 h. Non-adherent tumor cells were washed off in each sample, the remaining cells were fixed and counted in five different fields (5 × 0.25 mm2) using a phase contrast microscope. Mean values were calculated from five counts. Mean adhesion capacity is depicted as attached cells/mm2. One representative of six experiments is shown. *indicates significant difference to controls, #indicates significant difference to single drug treatment.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us